[Prognostic and predictive factors for endocrine treatment in breast carcinoma].
There is a long tradition for defining prognostic factors in breast carcinoma; the classic ones being lymphnode status, tumor size, malignancy grade, and hormone receptor status. More important are the detection of predictive factors, defined as factors in the tumor which predict the effect of a certain treatment. The hormone receptors are a classic example of predictive factors for determining whether patients should be offered endocrine treatment. New predictive factors are HER2 for predicting the effect of trastuzumab and TOP2A for predicting the effect of certain chemotherapies.
Knoop
Ann Søegaard
AS
Odense Universitetshospital, Onkologisk Afdeling R, Odense C. knoop@dadlnet.dk
Rasmussen
Birgitte Bruun
BB
D000367:Age Factors; D000951:Antigens, Neoplasm / Q000378:metabolism; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D009367:Neoplasm Staging; D000075223:Poly-ADP-Ribose Binding Proteins; D011237:Predictive Value of Tests; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D000075223:Poly-ADP-Ribose Binding Proteins; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D066246:ErbB Receptors; D004250:DNA Topoisomerases, Type II; C000618811:TOP2A protein, human